KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash & Equivalents (2016 - 2025)

Eli Lilly's Cash & Equivalents history spans 17 years, with the latest figure at $7.3 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 122.4% year-over-year to $7.3 billion; the TTM value through Dec 2025 reached $7.3 billion, up 122.4%, while the annual FY2025 figure was $7.3 billion, 122.4% up from the prior year.
  • Cash & Equivalents reached $7.3 billion in Q4 2025 per LLY's latest filing, down from $9.8 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $9.8 billion in Q3 2025 to a low of $2.1 billion in Q4 2022.
  • Average Cash & Equivalents over 5 years is $3.5 billion, with a median of $3.2 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: plummeted 45.87% in 2022, then surged 190.65% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $3.8 billion in 2021, then tumbled by 45.87% to $2.1 billion in 2022, then skyrocketed by 36.36% to $2.8 billion in 2023, then grew by 15.94% to $3.3 billion in 2024, then surged by 122.4% to $7.3 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Cash & Equivalents are $7.3 billion (Q4 2025), $9.8 billion (Q3 2025), and $3.4 billion (Q2 2025).